After Accelerate Diagnostics updated its investor deck with preliminary data from its FDA clinical trial, Piper Jaffray analyst William Quirk says he continues to expect FDA approval in Q3. The company announced "generally positive" preliminary FDA clinical trial results with AST data in line with the preclinical trial, Quirk tells investors in a research note. Accelerate's ID sensitivity of 94.6%, below the 95% endpoint and 96.6% from the preclinical trial, is unlikely to impact FDA approval given the "strong" AST results and faster turnaround time versus current systems, the analyst contends. He reiterates an Overweight rating on Accelerate Diagnostics with a $25 price target.